Select publications
Cunningham D et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004;351(4):337-45. Abstract
De Gramont A et al. Oxaliplatin/5FU/LV in the adjuvant treatment of stage II and stage III colon cancer: Efficacy results with a median follow-up of 4 years. Proc ASCO 2005;Abstract 3501.
O’Connell MJ et al. Relationship between tumor gene expression and recurrence in stage II/III colon cancer: Quantitative RT-PCR assay of 757 genes in fixed paraffin embedded (FPE) tissue. Proc ASCO 2006;Abstract 3518.
Peeters M et al. A phase 3, multicenter, randomized controlled trial (RCT) of panitumumab plus best supportive care (BSC) vs BSC alone in patients (pts) with metastatic colorectal cancer (mCRC). Proc AACR 2006;Abstract CP-1.
Rosenthal DI et al. ECOG 1297: A phase I study of preoperative radiation therapy (RT) with concurrent protracted continuous infusion 5-FU and dose escalating oxaliplatin followed by surgery, adjuvant 5-FU, and leucovorin for locally advanced (T3/4) rectal adenocarcinoma. Proc ASCO 2003;Abstract 1094.
Ryan DP et al. Phase I/II study of preoperative oxaliplatin, fluorouracil, and external beam radiation therapy in patients with locally advanced rectal cancer: Cancer and Leukemia Group B 89901. J Clin Oncol 2006;24(16):2557-62. Abstract
Saltz LB et al. Randomized phase II trial of cetuximab/bevacizumab/irinotecan (CBI) versus cetuximab/bevacizumab (CB) in irinotecan-refractory colorectal cancer. Proc ASCO 2005;Abstract 3508.
Wolmark N et al. A phase III trial comparing FULV to FULV + oxaliplatin in stage II or III carcinoma of the colon: Results of NSABP Protocol C-07. Proc ASCO 2005;Abstract 3500.
